TY - JOUR
T1 - Comparison of the therapeutic effects of CTVP and CTOP regimens as initial treatment for non-Hodgkin's lymphoma
AU - Hou, Yun
AU - Wang, Huaqing
AU - Fu, Kai
AU - Liu, Xianming
AU - Zhang, Huilai
AU - Qian, Zhengzi
AU - Li, Lanfang
AU - Zhou, Shiyong
AU - Cui, Xiuzhen
AU - Hao, Xishan
PY - 2010
Y1 - 2010
N2 - Objective: To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods: From January 2000 to December 2005, 288 patients with Non-Hodgkin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were 73.13% and 72.32%, the clinical benefit rates were 91.88% and 90.18%, respectively (P>0.05). Major toxicity was myelosuppression, Gl toxicity, fatigue, neurotoxicity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81% vs. 31.36%, P< 0.05). Median follow-up was 32 months (ranging from 2 to 71 months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2% and 22.3%, respectively (P<0.05). Conclusion: VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term survival. A randomized clinical trial is required to confirm these results.
AB - Objective: To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods: From January 2000 to December 2005, 288 patients with Non-Hodgkin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were 73.13% and 72.32%, the clinical benefit rates were 91.88% and 90.18%, respectively (P>0.05). Major toxicity was myelosuppression, Gl toxicity, fatigue, neurotoxicity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81% vs. 31.36%, P< 0.05). Median follow-up was 32 months (ranging from 2 to 71 months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2% and 22.3%, respectively (P<0.05). Conclusion: VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term survival. A randomized clinical trial is required to confirm these results.
KW - Doxorubicin
KW - Non-Hodgkin Lymphoma
KW - Vincristine
KW - Vindesine
UR - http://www.scopus.com/inward/record.url?scp=84873432683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873432683&partnerID=8YFLogxK
U2 - 10.3969/j.issn.1000-8179.2010.18.010
DO - 10.3969/j.issn.1000-8179.2010.18.010
M3 - Article
AN - SCOPUS:84873432683
VL - 37
SP - 1065
EP - 1068
JO - Chinese Journal of Clinical Oncology
JF - Chinese Journal of Clinical Oncology
SN - 1672-7118
IS - 18
ER -